IL-6-inducing whole yeast-based immunotherapy directly controls il-12-dependent CD8 T-cell responses

Journal of Immunotherapy

Volumn 35, Issue 1, 2012, Pages 14-22

  Tamburini, Beth A ^a   Kedl, Ross M ^a   Bellgrau, Donald ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

CD8 T cells; dendritic cell activation; IL 12; IL 6; whole yeast based immunotherapy

Indexed keywords

ALPHA CD40 ANTIBODY; ANTIBODY; B7 ANTIGEN; CD86 ANTIGEN; FUNGUS ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 6; PAM3CYS; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MEDICINAL YEAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH17 CELL; UPREGULATION;

ANIMALS; ANTIGENS, CD40; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYSTEINE; DENDRITIC CELLS; IMMUNOTHERAPY; INTERFERON TYPE I; INTERLEUKIN-12; INTERLEUKIN-6; LIPOPROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SACCHAROMYCES CEREVISIAE; TH17 CELLS; VACCINATION;

EID: 84155171317     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182356888     Document Type: Article

References (52)

1. Iwasaki A, Medzhitov R, Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291-295.
2. Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004;199:775-784.
3. Kurche JS, Burchill MA, Sanchez PJ, et al. Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses. J Immunol. 2010;185:2106-2115.
4. McWilliams JA, Sanchez PJ, Haluszczak C, et al. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine. 2010; 28:1468-1476.
5. Sanchez PJ, McWilliams JA, Haluszczak C, et al. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol. 2007;178:1564-1572.
6. Assudani D, Cho HI, DeVito N, et al. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res. 2008;68:9892-9899.
7. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
8. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474-478.
9. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
10. Netea MG, Brown GD, Kullberg BJ, et al. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol. 2008;6:67-78.
11. Curtsinger JM, Schmidt CS, Mondino A, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. 1999;162:3256-3262.
12. GlobeImmune. 2010. Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients with Genotype 1 Chronic Hepatitis C Infection. Available atError! Hyperlink reference not valid. Last Accessed date: September 26, 2011.
13. Bernstein MB, Chakraborty M, Wansley EK, et al. Recombi-nant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine. 2008;26:509-521.
14. Haller AA, Lauer GM, King TH, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007;25:1452-1463.
15. Lu Y, Bellgrau D, Dwyer-Nield LD, et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immuno-therapy. Cancer Res. 2004;64:5084-5088.
16. Riemann H, Takao J, Shellman YG, et al. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol. 2007;16:814-822.
17. Stubbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001;7:625-629.
18. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8: 639-646.
19. LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007;8:630-638.
20. Netea MG, Marodi L, Innate immune mechanisms for recognition and uptake of Candida species. Trends Immunol. 2010;31:346-353.
21. Palm NW, Medzhitov R. Antifungal defense turns 17. Nat Immunol. 2007;8:549-551.
22. Xiao Z, Casey KA, Jameson SC, et al. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol. 2009;182:2786-2794.
23. Mescher MF, Curtsinger JM, Agarwal P, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211:81-92.
24. Curtsinger JM, Valenzuela JO, Agarwal P, et al. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol. 2005;174:4465-4469.
25. Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol. 2002;169:6842-6849.
26. Kieper WC, Prlic M, Schmidt CS, et al. Il-12 enhances CD8 T cell homeostatic expansion. J Immunol. 2001;166:5515-5521.
27. Schmidt CS, Mescher MF. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. J Immunol. 1999; 163:2561-2567.
28. Grohmann U. Belladonna, ML, Bianchi, R, et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity. 1998;9:315-323.
29. Fukao T, Frucht DM, Yap G, et al. Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses. J Immunol. 2001;166: 4446-4455.
30. Driscoll M, Hansen R, Ding C, et al. Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol Ther. 2009;8:218-225.
31. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
32. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;15:114-123.
33. Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457-1464.
34. Aliberti J. Reis e Sousa, C, Schito, M, et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol. 2000;1:83-87.
35. Grumont R, Hochrein H, O'Keeffe M, et al. c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J Exp Med. 2001;194:1021-1032.
36. Iwasaki A, Kelsall BL. Unique functions of CD11b+, CD8 alpha+, and double-negative Peyer's patch dendritic cells. J Immunol. 2001;166:4884-4890.
37. Maldonado-Lopez R, De Smedt T, Michel P, et al. CD8al-pha+ and CD8alpha-subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med. 1999;189:587-592.
38. Schulz O, Edwards AD, Schito M, et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity. 2000;13:453-462.
39. Gearing AJ. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol Cell Biol. 2007;85:490-494.
40. Gaspari A, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol. 2009;8:467-474.
41. Dennehy KM, Willment JA, Williams DL, et al. Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. Eur J Immunol. 2009;39:1379-1386.
42. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361:1760-1767.
43. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727-1735.
44. Robinson MJ, Osorio F, Rosas M, et al. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med. 2009;206:2037-2051.
45. Torresi J, Johnson D, Wedemeyer H, Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54:1273-1285.
46. Langhans B, Kupfer B, Braunschweiger I, et al, Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011; 54:859-865.
47. Garcia-Hernandez Mde L, Hamada H, Reome JB, et al, Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol. 2011;184:4215-4227.
48. Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114: 596-599.
49. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787-798.
50. Dunn GP, Ikeda H, Bruce AT, et al. Interferon-gamma and cancer immunoediting. Immunol Res. 2005;32:231-245.
51. Boniface K, Blumenschein WM, Brovont-Porth K, et al, Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol. 2010;185:679-687.
52. Lee YK, Turner H, Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity. 2009;30: 92-107.